Asterion Signs Exclusive Definitive Association Agreement for $400 Million Financing, Development and Construction

Asterion Cannabis Inc. (“Asterion” or the “Company”), announces that the Company and its wholly-owned Australian subsidiary, Asterion (Australia) Pty Ltd., (“Asterion (Australia)”), has entered into an exclusive Definitive Association Agreement (DAA) on March 30, 2020, to finalize the development, construction, maintenance and financing of the first ($400 million) phase of its facilities in Toowoomba, Queensland, Australia (“Project”) with entities within the Watpac Limited group (“Watpac”).

Watpac is a large and well-known contractor in Australia and part of the BESIX Group, a global construction, property development and concessions company.

The DAA sets out a process for the parties to rapidly enter into Design and Construct and Facilities Maintenance agreements (or agreements of similar nature). As part of the DAA Watpac will work with Asterion to finalise acceptable standard Australian commercial terms for these agreements and separately investigate opportunities for investment in the Project.

Asterion’s Chairman and CEO, Mr. Stephen Van Deventer, commented, “This is a significant milestone achieved during the current global economic uncertainty and dynamic cannabis capital markets. Watpac and Asterion are aligned in the vision to bring our facility into successful and efficient production. Together we will work to finalise acceptable standard Australian commercial terms for funding and maintenance. Over the next few years Asterion coupled with Watpac’s skillset will set benchmarks within this rapidly evolving medical cannabis industry in the pharmaceutical sector.”

Watpac’s CEO, Jean-Pol Bouharmont, commented, “We are excited to be working with Asterion on this unique, next generation project and we look forward to bringing our expertise in project development, design, detailed engineering and construction of large-scale infrastructure to their proposed new Toowoomba facility. It’s scale and unique combination of the advanced intensive horticulture and pharmaceutical grade processes and products presents an exciting opportunity for us. ”.

Asterion is currently in the process of completing a non-brokered private placement for $10 million equity at $1.50 per share with a half warrant, each whole warrant entitling the holder thereof to purchase an additional share at $2.00 per share for two years subject to an accelerator. Only accredited and sophisticated investors may participate. The proceeds of these funds will be used for operations and implementing sales of medical cannabis to registered Australian medical patients. All securities issued under the non-brokered private placement will be subject to a hold period of four months and one day in Canada.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States, or in any jurisdiction in which such an offer or sale would be unlawful. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any United States state securities laws, and may not be offered or sold in the United States or to the account or benefit of a “U.S. person” (as defined in Regulation S under the 1933 Act) or a person in the United States absent registration or an applicable exemption from the registration requirements.

About Asterion

Asterion Cannabis Inc. is a Canadian medicinal cannabis company with a wholly-owned Australian subsidiary, Asterion (Australia) Pty Ltd. With its cultivation to market strategy, the company’s focus is leading and advancing cannabis agriculture, producing the highest quality, low cost, genetically uniform cannabis strains and cannabinoid products for global supply. The Australian government formally recognizes the company with a Major Project Status and the company has been granted a medicinal cannabis license, a cannabis research license, and a manufacture license from the Australian Office of Drug Control.

Led by a highly experienced team with over 200 years of combined relevant credentials spanning – North America, Europe, the Middle East, and Asia-Pacific. Management experience with large scale projects includes medicinal cannabis, renewable energy, and capital markets.

About Watpac

Watpac is a leading national construction group with operations across Australia’s East Coast and South Australia and the Northern Territory. Watpac has been part of Australia’s communities for nearly four decades and through previous entities since the 1920s. Watpac employs around 700 people, and in December 2018, Watpac became a wholly owned subsidiary of BESIX Group. BESIX is a multidisciplinary contracting company founded in Belgium more than 100 years ago. The company specialises in complex construction, infrastructure and marine works with a focus on value creation across the project lifecycle. BESIX employs around 15,000 people globally. More information is available at www.watpac.com.au

On Behalf of the Board of Directors

“Stephen Van Deventer”

Chairman & CEO

For further information, please contact:

Investor Relations

IR@asterioncannabis.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the amount of the non-brokered private placement, the intended use of proceeds of the non-brokered private placement, the construction of the Project, the financial investment in the Project and provision of maintenance services following the completion of the construction of the Project by the Finance Company and the Company’s anticipated business plans and prospect of success in executing its plans. Often, but not always, forward-looking statements can be identified by words such as “plans”, “expects”, “may”, “will”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, industry trends, growth opportunities, and the Company and Asterion Australia’s expectations that Asterion Australia will be granted the necessary permits and be able to continue to obtain the financing needed to complete the Project and to carry out its planned future activities, retain and attract qualified personnel and obtain and/or maintain the necessary rights or permits needed to carry out its future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the inability of the Company and/or Asterion (Australia) to, among other things, successfully complete the non-brokered private placement, successfully complete the Project, obtain the required regulatory approvals and financing required for the construction and operation of the Project, execute its proposed business plans, and carry out its planned future activities. Other factors such as general economic, market or business conditions, outbreaks of infectious diseases or the occurrence of pandemics, such as the recent outbreak of the novel coronavirus COVID-19, or changes in laws, regulations and policies affecting the biotechnology or medical cannabis industry and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company and Asterion (Australia). These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

Click here to connect with Asterion Cannabis Inc. for an Investor Presentation.

Source

Asterion Appoints Amy Stephenson as Chief Investment Officer

Asterion Cannabis Inc. (“Asterion” or the “Company”), announces the appointment of Amy Stephenson, MBA, CFA, CPA, CMA, as Chief Investment Officer.

Amy Stephenson has the in-depth cannabis industry knowledge, experience and relationship collateral that allows her to provide relevant information, direction and leadership on optimal financing and public transaction strategies for cannabis companies during the infancy stage. Ms. Stephenson’s addition to the team brings Asterion, one of the most accomplished finance officers in the industry.

Keep reading... Show less

Bitcoin Investing in Australia

Bitcoin is experiencing hype as its price continues to ride high, and Aussie investors are looking closer at ways to invest in cryptocurrencies.

Debuting in 2010 at a cost of just a cent, bitcoin has since taken off, reaching a record-breaking value of more than US$63,000 this past April, equivalent to over AU$81,000.

The market is gaining steam, and research from Finder shows that one in four Australians are currently investing in cryptocurrencies, with 13 percent putting money in bitcoin. Almost half of the cryptocurrency investors surveyed by Finder said they purchased digital coins due to their skyrocketing value.

Keep reading... Show less

Asterion Appoints Amy Stephenson as Chief Investment Officer

Asterion Cannabis Inc. (“Asterion” or the “Company”), announces the appointment of Amy Stephenson, MBA, CFA, CPA, CMA, as Chief Investment Officer.

Amy Stephenson has the in-depth cannabis industry knowledge, experience and relationship collateral that allows her to provide relevant information, direction and leadership on optimal financing and public transaction strategies for cannabis companies during the infancy stage. Ms. Stephenson’s addition to the team brings Asterion, one of the most accomplished finance officers in the industry.

Keep reading... Show less

Asterion Cannabis to Participate in the 32nd Annual ROTH Conference

Asterion Cannabis Inc. (“Asterion” or the “Company”), is pleased to announce that it will participate in the 32nd Annual ROTH Conference taking place in Orange County, California, USA, from March 15th – 17th, 2020. Asterion’s Chairman and CEO Stephen Van Deventer will be presenting, as a private company, on March 16th. Stephen will also be conducting one-on-one meetings with investors at the conference.

ROTH Conference, hosted by ROTH Capital Partners, is one of the premier small and mid-cap investor conferences in the U.S. The event gathers close to 550 participating companies and over 5,100 attendees. It will feature presentations from public and private companies in a variety of sectors, from cleantech to metals and mining to health and wellness, including healthcare. For additional details about the conference, please visit www.roth.com/occonference.

Keep reading... Show less

Australia Mining Update: H1 2021 in Review

Click here to read the previous Australia mining update.

After an uncertain 2020 for the Australian mining industry, the resource market showed signs of a sharp recovery in the first six months of the new year.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

Investing in Lithium in Australia

After the country became the world’s largest lithium producer in 2018, many market participants are wondering if investing in lithium in Australia is a good option

Without a doubt, the energy revolution is here to stay, with forecasts for electric vehicle (EV) sales increasing every day. As a result, demand for lithium, a key element in the lithium-ion batteries used to power electric cars, is expected to triple by 2025 — reaching about 1 million tonnes in size.

Keep reading... Show less

How to Buy Bitcoin in Australia

Investors looking for decentralised assets (and potentially major gains) in a post-COVID-19 Australia are turning in droves to cryptocurrencies.

Bitcoin in particular is getting Aussies excited after its price hit record highs in March 2021, and again the next month. As a finite resource, its volatility is proving exciting for many market watchers.

For those interested in jumping into the space, the Investing News Network has put together a step-by-step guide on how to start buying bitcoin in Australia — and how to stay safe while doing so.

Keep reading... Show less

Nickel Stocks in Western Australia

Nickel gets a lot of love these days. Besides its applications as a base metal, it's discovering a rising popularity as an electric vehicle metal thanks to its role in battery technology.

Nickel is a vital component in lithium-ion batteries, which are seeing "hockey stick"-like production rates around the world as electric vehicles become more prevalent.

According to the Australian government, the country holds around 19.7 million tonnes in economic demonstrated reserves of the metal, making it a top nation for nickel reserves, as well as a top nation for nickel production with 180,000 tonnes produced in 2019.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

When Will Australia Legalise Recreational Cannabis?

Recreational cannabis remains illegal in all Australia’s states and territories with the exception of the Australian Capital Territory (ACT). But could that change in the future?

So far there are no clear indicators as to when or if Australia could legalise recreational cannabis, but attitudes seem to be changing. Public support is growing, and there’s even some political acceptance.

Read on to learn more about when Australia may legalise recreational cannabis.

Keep reading... Show less

A State-by-State Guide to Cannabis in Australia

Australia made waves when it federally legalised medicinal cannabis in 2016, and its marijuana market has experienced significant growth since then.

A study from FreshLeaf Analytics pegs Australian medical market sales at AU$95 million in 2020, while research firm Prohibition Partners indicates that Oceania’s cannabis industry is expected to be worth US$1.55 billion by 2024; medicinal cannabis is expected to account for 40 percent of the industry.

Despite that growth, the country’s cannabis industry is still young. Recreational use is not yet in sight, and even medical access remains limited and highly regulated.

Keep reading... Show less

Australian Cannabis: Forecasts, Analysis and Expert Advice

Are you ready to start investing in Australia’s growing cannabis market?

Dive right in with our FREE Special Report, Australian Cannabis: Forecasts, Analysis and Expert Advice

Keep reading... Show less

Cannabis in the ACT: The Market a Year Post-Legalisation

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Top News

Related News